Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.96 | N/A | -256.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.96 | N/A | -256.27% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing product development.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the earnings miss.
The earnings report indicates that PTC Therapeutics is facing significant challenges, particularly reflected in their EPS miss. The stock's decline of 1.96% suggests that investors are reacting cautiously to the lack of revenue information and future guidance. Management's focus on product development may help in the long term, but immediate concerns remain.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
INSULET CORP
Feb 25, 2019